NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $3.83 -0.02 (-0.52%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Cingulate Stock (NASDAQ:CING) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cingulate alerts:Sign Up Key Stats Today's Range$3.80▼$3.9450-Day Range$3.83▼$9.8852-Week Range$1.80▼$152.40Volume43,413 shsAverage Volume1.20 million shsMarket Capitalization$11.66 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company OverviewCingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Cingulate Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreCING MarketRank™: Cingulate scored higher than 49% of companies evaluated by MarketBeat, and ranked 625th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCingulate has received no research coverage in the past 90 days.Read more about Cingulate's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cingulate are expected to grow in the coming year, from ($12.51) to ($4.76) per share.Read more about Cingulate's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.87% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently increased by 37.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.87% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently increased by 37.28%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment-0.38 News SentimentCingulate has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cingulate this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added Cingulate to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $842.00 in company stock.Percentage Held by Insiders17.06% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address CING Stock News HeadlinesEsketamine Also Effective Without Adjunctive AntidepressantNovember 4 at 7:11 PM | msn.comWhy the silent treatment is straight up abusiveNovember 2 at 7:14 AM | yahoo.comCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.November 5, 2024 | Timothy Sykes (Ad)How Much Of Your Political Ideology Is Due To Your Brain Structure?October 30, 2024 | forbes.comScientists find brain network is doubled in size in depressed peopleOctober 28, 2024 | msn.comHow the Sound of Music Can Be Healing. Literally.October 27, 2024 | nytimes.comThe effects of binge drinking on teenagers' brain developmentOctober 23, 2024 | msn.comNeuroscientists uncover brain mechanisms underlying political myside biasOctober 16, 2024 | msn.comSee More Headlines CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING stock has decreased by 49.9% and is now trading at $3.83. View the best growth stocks for 2024 here. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($5.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.64) by $0.17. When did Cingulate's stock split? Cingulate shares reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cingulate own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO). Company Calendar Last Earnings8/13/2024Today11/04/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+108.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-382.24% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($70.63) per share Price / Book-0.05Miscellaneous Outstanding Shares3,044,000Free Float2,525,000Market Cap$11.66 million OptionableNot Optionable Beta-0.89 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:CING) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.